Bio News
Beacon Therapeutics said its gene therapy for X-linked retinitis pigmentosa (XLRP), laruparetigene jovaparvovec (laru-jova), met the primary endpoint in a late-stage trial.
The percentage of patients who showed an improvement of at least 15 letters on a low-luminance visual acuity test was 24% in the low-dose group and 31% in the high-dose group, compared with 0% in the control group.
Beacon plans to begin rolling regulatory submissions by the end of the year and disclose detailed data at a medical meeting in October.
BIOBOOK TEAM
biobookmedia@biobook.co.krKorea National Park Service Uses AI to Identify 17 Wildlife Species, Cuts Analysis Time by 99%
Ipscell Receives Notice of Allowance for Universal iPSC Patent, Strengthening Cell Line Supply Business
Ministry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
Paragon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Korea National Park Service Uses AI to Identify 17 Wildlife Species, Cuts Analysis Time by 99%
Ipscell Receives Notice of Allowance for Universal iPSC Patent, Strengthening Cell Line Supply Business
Ministry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
